Stem Cell Therapy Comprehensive Study by Type (Autologous, Allogeneic), Application (CNS, CVS, GIT, Wounds and Injuries, Musculoskeletal, Eye, Immune System, Others), Cell Source (Adipose tissue, Bone Marrow, Embro/Cord Blood Derived, IPSCs (Induced Pluripotent Stem Cell)), End user (Therapeutic Companies, Cell and Tissue Banks, Tools and Reagents Companies, Service Companies, Hospitals) Players and Region - Global Market Outlook to 2026

Stem Cell Therapy Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 13.8%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Stem Cell TherapyMarket?
With the increasing advances in science and technology and awareness about stem cell therapy has also increased. In many countries with universal health coverage, individuals may be paid by the government to be treated in other countries. These steps improve the patientís accessibility and hence, the perception to consider stem cell as a feasible option.Stem cells are the most vital cells that are found in both humans and non-human animals. Stem cells are also known as the centerpiece of regenerative medicine. Regenerative medicines have the capability to grow new cells and replace damaged and dead cells. The stem cell is the precursors of all cells in the human body that has the ability to replicate itself and repair and replace other damaged tissues in the human body. In addition, stem cell-based therapies are used in the treatment of several chronic diseases such as cancer and blood disorders.

Market Trend
Increasing cost of stem cell therapy procedure and Technological advancement in healthcare and identification of new stem cell line.

Market Drivers
Significant rise in the number of clinical application of stem cells and advantages of stem cell therapies, Rapid infrastructure development and increasing disposable income of the consumers, Increasing awareness among people about therapeutic potency of stem cells and Technology advancement in healthcare curing life threatening diseases and giving promising results.

Opportunities
Rise in Economy and technological advancement may provide opportunities for this market.

The Players Covered in the Study are:
Cellular Dynamics International, Inc. (United States), Osiris Therapeutics (United States), Vcanbio Cell & Gene Corp. Ltd. (United States), Gamida-Cell Ltd. (Israel), Golden Meditech Holdings Limited (Hong Kong), Celgene Corp. (United States), Guanhao Biotech Co. (China), Mesoblast Ltd. (Australia), Vericel Corp. (United States), Stemcell Technologies Inc. (Canada), Beike Biotechnology co., Ltd. (China), Cytori Therapeutics, Inc. (United States), Bioheart Inc. (United States), Universal Cells, Inc. (Japan), Athersys, Inc. (United States), Geron Corp. (United States), Pluristem Therapeutics (Israel), Fibrocell Science (United States), Astellas US Holding, Inc. (United States), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (United States), RTI Surgical, Inc. (United States), AlloSource (United States), Novartis International AG (Switzerland) and Gilead Sciences (United States)

Available Customization:
List of players that can be included in the study on immediate basis are Organogenesis Holdings (United States), Vericel (United States), Mesoblast Ltd.(Australia), ReNueron Group plc,(United Kingdom) and International Stem Cell Corp. (United States).

Report Objectives / Segmentation Covered

By Type
  • Autologous
  • Allogeneic
By Application
  • CNS
  • CVS
  • GIT
  • Wounds and Injuries
  • Musculoskeletal
  • Eye
  • Immune System
  • Others
By Cell Source
  • Adipose tissue
  • Bone Marrow
  • Embro/Cord Blood Derived
  • IPSCs (Induced Pluripotent Stem Cell)

By End user
  • Therapeutic Companies
  • Cell and Tissue Banks
  • Tools and Reagents Companies
  • Service Companies
  • Hospitals

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Significant rise in the number of clinical application of stem cells and advantages of stem cell therapies
      • 3.2.2. Rapid infrastructure development and increasing disposable income of the consumers
      • 3.2.3. Increasing awareness among people about therapeutic potency of stem cells
      • 3.2.4. Technology advancement in healthcare curing life threatening diseases and giving promising results.
    • 3.3. Market Challenges
      • 3.3.1. Complexity related with preservation of stem cells
      • 3.3.2. Rising cost of the clinical trials conducted for stem cell therapy by the researchers.
    • 3.4. Market Trends
      • 3.4.1. Increasing cost of stem cell therapy procedure
      • 3.4.2. Technological advancement in healthcare and identification of new stem cell line.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Stem Cell Therapy, by Type, Application, Cell Source, End user and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Stem Cell Therapy (Value)
      • 5.2.1. Global Stem Cell Therapy by: Type (Value)
        • 5.2.1.1. Autologous
        • 5.2.1.2. Allogeneic
      • 5.2.2. Global Stem Cell Therapy by: Application (Value)
        • 5.2.2.1. CNS
        • 5.2.2.2. CVS
        • 5.2.2.3. GIT
        • 5.2.2.4. Wounds and Injuries
        • 5.2.2.5. Musculoskeletal
        • 5.2.2.6. Eye
        • 5.2.2.7. Immune System
        • 5.2.2.8. Others
      • 5.2.3. Global Stem Cell Therapy by: Cell Source (Value)
        • 5.2.3.1. Adipose tissue
        • 5.2.3.2. Bone Marrow
        • 5.2.3.3. Embro/Cord Blood Derived
        • 5.2.3.4. IPSCs (Induced Pluripotent Stem Cell)
      • 5.2.4. Global Stem Cell Therapy by: End user (Value)
        • 5.2.4.1. Therapeutic Companies
        • 5.2.4.2. Cell and Tissue Banks
        • 5.2.4.3. Tools and Reagents Companies
        • 5.2.4.4. Service Companies
        • 5.2.4.5. Hospitals
      • 5.2.5. Global Stem Cell Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Stem Cell Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cellular Dynamics International, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Osiris Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Vcanbio Cell & Gene Corp. Ltd. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gamida-Cell Ltd. (Israel)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Golden Meditech Holdings Limited (Hong Kong)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Celgene Corp. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Guanhao Biotech Co. (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mesoblast Ltd. (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vericel Corp. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Stemcell Technologies Inc. (Canada)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Beike Biotechnology co., Ltd. (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Cytori Therapeutics, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Bioheart Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Universal Cells, Inc. (Japan)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Athersys, Inc. (United States)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Geron Corp. (United States)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
      • 6.4.17. Pluristem Therapeutics (Israel)
        • 6.4.17.1. Business Overview
        • 6.4.17.2. Products/Services Offerings
        • 6.4.17.3. Financial Analysis
        • 6.4.17.4. SWOT Analysis
      • 6.4.18. Fibrocell Science (United States)
        • 6.4.18.1. Business Overview
        • 6.4.18.2. Products/Services Offerings
        • 6.4.18.3. Financial Analysis
        • 6.4.18.4. SWOT Analysis
      • 6.4.19. Astellas US Holding, Inc. (United States)
        • 6.4.19.1. Business Overview
        • 6.4.19.2. Products/Services Offerings
        • 6.4.19.3. Financial Analysis
        • 6.4.19.4. SWOT Analysis
      • 6.4.20. MEDIPOST Co., Ltd. (South Korea)
        • 6.4.20.1. Business Overview
        • 6.4.20.2. Products/Services Offerings
        • 6.4.20.3. Financial Analysis
        • 6.4.20.4. SWOT Analysis
      • 6.4.21. Anterogen Co., Ltd. (South Korea)
        • 6.4.21.1. Business Overview
        • 6.4.21.2. Products/Services Offerings
        • 6.4.21.3. Financial Analysis
        • 6.4.21.4. SWOT Analysis
      • 6.4.22. Pharmicell Co., Ltd. (South Korea)
        • 6.4.22.1. Business Overview
        • 6.4.22.2. Products/Services Offerings
        • 6.4.22.3. Financial Analysis
        • 6.4.22.4. SWOT Analysis
      • 6.4.23. Holostem Terapie Avanzate S.r.l (Italy)
        • 6.4.23.1. Business Overview
        • 6.4.23.2. Products/Services Offerings
        • 6.4.23.3. Financial Analysis
        • 6.4.23.4. SWOT Analysis
      • 6.4.24. JCR Pharmaceuticals Co., Ltd. (Japan)
        • 6.4.24.1. Business Overview
        • 6.4.24.2. Products/Services Offerings
        • 6.4.24.3. Financial Analysis
        • 6.4.24.4. SWOT Analysis
      • 6.4.25. NuVasive, Inc. (United States)
        • 6.4.25.1. Business Overview
        • 6.4.25.2. Products/Services Offerings
        • 6.4.25.3. Financial Analysis
        • 6.4.25.4. SWOT Analysis
      • 6.4.26. RTI Surgical, Inc. (United States)
        • 6.4.26.1. Business Overview
        • 6.4.26.2. Products/Services Offerings
        • 6.4.26.3. Financial Analysis
        • 6.4.26.4. SWOT Analysis
      • 6.4.27. AlloSource (United States)
        • 6.4.27.1. Business Overview
        • 6.4.27.2. Products/Services Offerings
        • 6.4.27.3. Financial Analysis
        • 6.4.27.4. SWOT Analysis
      • 6.4.28. Novartis International AG (Switzerland)
        • 6.4.28.1. Business Overview
        • 6.4.28.2. Products/Services Offerings
        • 6.4.28.3. Financial Analysis
        • 6.4.28.4. SWOT Analysis
      • 6.4.29. Gilead Sciences (United States)
        • 6.4.29.1. Business Overview
        • 6.4.29.2. Products/Services Offerings
        • 6.4.29.3. Financial Analysis
        • 6.4.29.4. SWOT Analysis
  • 7. Global Stem Cell Therapy Sale, by Type, Application, Cell Source, End user and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Stem Cell Therapy (Value)
      • 7.2.1. Global Stem Cell Therapy by: Type (Value)
        • 7.2.1.1. Autologous
        • 7.2.1.2. Allogeneic
      • 7.2.2. Global Stem Cell Therapy by: Application (Value)
        • 7.2.2.1. CNS
        • 7.2.2.2. CVS
        • 7.2.2.3. GIT
        • 7.2.2.4. Wounds and Injuries
        • 7.2.2.5. Musculoskeletal
        • 7.2.2.6. Eye
        • 7.2.2.7. Immune System
        • 7.2.2.8. Others
      • 7.2.3. Global Stem Cell Therapy by: Cell Source (Value)
        • 7.2.3.1. Adipose tissue
        • 7.2.3.2. Bone Marrow
        • 7.2.3.3. Embro/Cord Blood Derived
        • 7.2.3.4. IPSCs (Induced Pluripotent Stem Cell)
      • 7.2.4. Global Stem Cell Therapy by: End user (Value)
        • 7.2.4.1. Therapeutic Companies
        • 7.2.4.2. Cell and Tissue Banks
        • 7.2.4.3. Tools and Reagents Companies
        • 7.2.4.4. Service Companies
        • 7.2.4.5. Hospitals
      • 7.2.5. Global Stem Cell Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Stem Cell Therapy: by Type(USD Million)
  • Table 2. Stem Cell Therapy Autologous , by Region USD Million (2015-2020)
  • Table 3. Stem Cell Therapy Allogeneic , by Region USD Million (2015-2020)
  • Table 4. Stem Cell Therapy: by Application(USD Million)
  • Table 5. Stem Cell Therapy CNS , by Region USD Million (2015-2020)
  • Table 6. Stem Cell Therapy CVS , by Region USD Million (2015-2020)
  • Table 7. Stem Cell Therapy GIT , by Region USD Million (2015-2020)
  • Table 8. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2015-2020)
  • Table 9. Stem Cell Therapy Musculoskeletal , by Region USD Million (2015-2020)
  • Table 10. Stem Cell Therapy Eye , by Region USD Million (2015-2020)
  • Table 11. Stem Cell Therapy Immune System , by Region USD Million (2015-2020)
  • Table 12. Stem Cell Therapy Others , by Region USD Million (2015-2020)
  • Table 13. Stem Cell Therapy: by Cell Source(USD Million)
  • Table 14. Stem Cell Therapy Adipose tissue , by Region USD Million (2015-2020)
  • Table 15. Stem Cell Therapy Bone Marrow , by Region USD Million (2015-2020)
  • Table 16. Stem Cell Therapy Embro/Cord Blood Derived , by Region USD Million (2015-2020)
  • Table 17. Stem Cell Therapy IPSCs (Induced Pluripotent Stem Cell) , by Region USD Million (2015-2020)
  • Table 18. Stem Cell Therapy: by End user(USD Million)
  • Table 19. Stem Cell Therapy Therapeutic Companies , by Region USD Million (2015-2020)
  • Table 20. Stem Cell Therapy Cell and Tissue Banks , by Region USD Million (2015-2020)
  • Table 21. Stem Cell Therapy Tools and Reagents Companies , by Region USD Million (2015-2020)
  • Table 22. Stem Cell Therapy Service Companies , by Region USD Million (2015-2020)
  • Table 23. Stem Cell Therapy Hospitals , by Region USD Million (2015-2020)
  • Table 24. South America Stem Cell Therapy, by Country USD Million (2015-2020)
  • Table 25. South America Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 26. South America Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 27. South America Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 28. South America Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 29. Brazil Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 30. Brazil Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 31. Brazil Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 32. Brazil Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 33. Argentina Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 34. Argentina Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 35. Argentina Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 36. Argentina Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 37. Rest of South America Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 38. Rest of South America Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 39. Rest of South America Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 40. Rest of South America Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 41. Asia Pacific Stem Cell Therapy, by Country USD Million (2015-2020)
  • Table 42. Asia Pacific Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 43. Asia Pacific Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 44. Asia Pacific Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 45. Asia Pacific Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 46. China Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 47. China Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 48. China Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 49. China Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 50. Japan Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 51. Japan Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 52. Japan Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 53. Japan Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 54. India Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 55. India Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 56. India Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 57. India Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 58. South Korea Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 59. South Korea Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 60. South Korea Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 61. South Korea Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 62. Taiwan Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 63. Taiwan Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 64. Taiwan Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 65. Taiwan Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 66. Australia Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 67. Australia Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 68. Australia Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 69. Australia Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 73. Rest of Asia-Pacific Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 74. Europe Stem Cell Therapy, by Country USD Million (2015-2020)
  • Table 75. Europe Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 76. Europe Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 77. Europe Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 78. Europe Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 79. Germany Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 80. Germany Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 81. Germany Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 82. Germany Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 83. France Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 84. France Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 85. France Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 86. France Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 87. Italy Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 88. Italy Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 89. Italy Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 90. Italy Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 91. United Kingdom Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 92. United Kingdom Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 93. United Kingdom Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 94. United Kingdom Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 95. Netherlands Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 96. Netherlands Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 97. Netherlands Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 98. Netherlands Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 99. Rest of Europe Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 100. Rest of Europe Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 101. Rest of Europe Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 102. Rest of Europe Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 103. MEA Stem Cell Therapy, by Country USD Million (2015-2020)
  • Table 104. MEA Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 105. MEA Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 106. MEA Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 107. MEA Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 108. Middle East Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 109. Middle East Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 110. Middle East Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 111. Middle East Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 112. Africa Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 113. Africa Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 114. Africa Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 115. Africa Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 116. North America Stem Cell Therapy, by Country USD Million (2015-2020)
  • Table 117. North America Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 118. North America Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 119. North America Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 120. North America Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 121. United States Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 122. United States Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 123. United States Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 124. United States Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 125. Canada Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 126. Canada Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 127. Canada Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 128. Canada Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 129. Mexico Stem Cell Therapy, by Type USD Million (2015-2020)
  • Table 130. Mexico Stem Cell Therapy, by Application USD Million (2015-2020)
  • Table 131. Mexico Stem Cell Therapy, by Cell Source USD Million (2015-2020)
  • Table 132. Mexico Stem Cell Therapy, by End user USD Million (2015-2020)
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Company Basic Information, Sales Area and Its Competitors
  • Table 151. Company Basic Information, Sales Area and Its Competitors
  • Table 152. Company Basic Information, Sales Area and Its Competitors
  • Table 153. Company Basic Information, Sales Area and Its Competitors
  • Table 154. Company Basic Information, Sales Area and Its Competitors
  • Table 155. Company Basic Information, Sales Area and Its Competitors
  • Table 156. Company Basic Information, Sales Area and Its Competitors
  • Table 157. Company Basic Information, Sales Area and Its Competitors
  • Table 158. Company Basic Information, Sales Area and Its Competitors
  • Table 159. Company Basic Information, Sales Area and Its Competitors
  • Table 160. Company Basic Information, Sales Area and Its Competitors
  • Table 161. Company Basic Information, Sales Area and Its Competitors
  • Table 162. Stem Cell Therapy: by Type(USD Million)
  • Table 163. Stem Cell Therapy Autologous , by Region USD Million (2021-2026)
  • Table 164. Stem Cell Therapy Allogeneic , by Region USD Million (2021-2026)
  • Table 165. Stem Cell Therapy: by Application(USD Million)
  • Table 166. Stem Cell Therapy CNS , by Region USD Million (2021-2026)
  • Table 167. Stem Cell Therapy CVS , by Region USD Million (2021-2026)
  • Table 168. Stem Cell Therapy GIT , by Region USD Million (2021-2026)
  • Table 169. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2021-2026)
  • Table 170. Stem Cell Therapy Musculoskeletal , by Region USD Million (2021-2026)
  • Table 171. Stem Cell Therapy Eye , by Region USD Million (2021-2026)
  • Table 172. Stem Cell Therapy Immune System , by Region USD Million (2021-2026)
  • Table 173. Stem Cell Therapy Others , by Region USD Million (2021-2026)
  • Table 174. Stem Cell Therapy: by Cell Source(USD Million)
  • Table 175. Stem Cell Therapy Adipose tissue , by Region USD Million (2021-2026)
  • Table 176. Stem Cell Therapy Bone Marrow , by Region USD Million (2021-2026)
  • Table 177. Stem Cell Therapy Embro/Cord Blood Derived , by Region USD Million (2021-2026)
  • Table 178. Stem Cell Therapy IPSCs (Induced Pluripotent Stem Cell) , by Region USD Million (2021-2026)
  • Table 179. Stem Cell Therapy: by End user(USD Million)
  • Table 180. Stem Cell Therapy Therapeutic Companies , by Region USD Million (2021-2026)
  • Table 181. Stem Cell Therapy Cell and Tissue Banks , by Region USD Million (2021-2026)
  • Table 182. Stem Cell Therapy Tools and Reagents Companies , by Region USD Million (2021-2026)
  • Table 183. Stem Cell Therapy Service Companies , by Region USD Million (2021-2026)
  • Table 184. Stem Cell Therapy Hospitals , by Region USD Million (2021-2026)
  • Table 185. South America Stem Cell Therapy, by Country USD Million (2021-2026)
  • Table 186. South America Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 187. South America Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 188. South America Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 189. South America Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 190. Brazil Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 191. Brazil Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 192. Brazil Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 193. Brazil Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 194. Argentina Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 195. Argentina Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 196. Argentina Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 197. Argentina Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 198. Rest of South America Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 199. Rest of South America Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 200. Rest of South America Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 201. Rest of South America Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 202. Asia Pacific Stem Cell Therapy, by Country USD Million (2021-2026)
  • Table 203. Asia Pacific Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 204. Asia Pacific Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 205. Asia Pacific Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 206. Asia Pacific Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 207. China Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 208. China Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 209. China Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 210. China Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 211. Japan Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 212. Japan Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 213. Japan Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 214. Japan Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 215. India Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 216. India Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 217. India Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 218. India Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 219. South Korea Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 220. South Korea Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 221. South Korea Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 222. South Korea Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 223. Taiwan Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 224. Taiwan Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 225. Taiwan Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 226. Taiwan Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 227. Australia Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 228. Australia Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 229. Australia Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 230. Australia Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 231. Rest of Asia-Pacific Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 232. Rest of Asia-Pacific Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 233. Rest of Asia-Pacific Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 234. Rest of Asia-Pacific Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 235. Europe Stem Cell Therapy, by Country USD Million (2021-2026)
  • Table 236. Europe Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 237. Europe Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 238. Europe Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 239. Europe Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 240. Germany Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 241. Germany Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 242. Germany Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 243. Germany Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 244. France Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 245. France Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 246. France Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 247. France Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 248. Italy Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 249. Italy Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 250. Italy Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 251. Italy Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 252. United Kingdom Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 253. United Kingdom Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 254. United Kingdom Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 255. United Kingdom Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 256. Netherlands Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 257. Netherlands Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 258. Netherlands Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 259. Netherlands Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 260. Rest of Europe Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 261. Rest of Europe Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 262. Rest of Europe Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 263. Rest of Europe Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 264. MEA Stem Cell Therapy, by Country USD Million (2021-2026)
  • Table 265. MEA Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 266. MEA Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 267. MEA Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 268. MEA Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 269. Middle East Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 270. Middle East Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 271. Middle East Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 272. Middle East Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 273. Africa Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 274. Africa Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 275. Africa Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 276. Africa Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 277. North America Stem Cell Therapy, by Country USD Million (2021-2026)
  • Table 278. North America Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 279. North America Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 280. North America Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 281. North America Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 282. United States Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 283. United States Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 284. United States Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 285. United States Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 286. Canada Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 287. Canada Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 288. Canada Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 289. Canada Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 290. Mexico Stem Cell Therapy, by Type USD Million (2021-2026)
  • Table 291. Mexico Stem Cell Therapy, by Application USD Million (2021-2026)
  • Table 292. Mexico Stem Cell Therapy, by Cell Source USD Million (2021-2026)
  • Table 293. Mexico Stem Cell Therapy, by End user USD Million (2021-2026)
  • Table 294. Research Programs/Design for This Report
  • Table 295. Key Data Information from Secondary Sources
  • Table 296. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Stem Cell Therapy: by Type USD Million (2015-2020)
  • Figure 5. Global Stem Cell Therapy: by Application USD Million (2015-2020)
  • Figure 6. Global Stem Cell Therapy: by Cell Source USD Million (2015-2020)
  • Figure 7. Global Stem Cell Therapy: by End user USD Million (2015-2020)
  • Figure 8. South America Stem Cell Therapy Share (%), by Country
  • Figure 9. Asia Pacific Stem Cell Therapy Share (%), by Country
  • Figure 10. Europe Stem Cell Therapy Share (%), by Country
  • Figure 11. MEA Stem Cell Therapy Share (%), by Country
  • Figure 12. North America Stem Cell Therapy Share (%), by Country
  • Figure 13. Global Stem Cell Therapy share by Players 2020 (%)
  • Figure 14. Global Stem Cell Therapy share by Players (Top 3) 2020(%)
  • Figure 15. Global Stem Cell Therapy share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Cellular Dynamics International, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Cellular Dynamics International, Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Osiris Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 20. Osiris Therapeutics (United States) Revenue: by Geography 2020
  • Figure 21. Vcanbio Cell & Gene Corp. Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Vcanbio Cell & Gene Corp. Ltd. (United States) Revenue: by Geography 2020
  • Figure 23. Gamida-Cell Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 24. Gamida-Cell Ltd. (Israel) Revenue: by Geography 2020
  • Figure 25. Golden Meditech Holdings Limited (Hong Kong) Revenue, Net Income and Gross profit
  • Figure 26. Golden Meditech Holdings Limited (Hong Kong) Revenue: by Geography 2020
  • Figure 27. Celgene Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Celgene Corp. (United States) Revenue: by Geography 2020
  • Figure 29. Guanhao Biotech Co. (China) Revenue, Net Income and Gross profit
  • Figure 30. Guanhao Biotech Co. (China) Revenue: by Geography 2020
  • Figure 31. Mesoblast Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 32. Mesoblast Ltd. (Australia) Revenue: by Geography 2020
  • Figure 33. Vericel Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Vericel Corp. (United States) Revenue: by Geography 2020
  • Figure 35. Stemcell Technologies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 36. Stemcell Technologies Inc. (Canada) Revenue: by Geography 2020
  • Figure 37. Beike Biotechnology co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 38. Beike Biotechnology co., Ltd. (China) Revenue: by Geography 2020
  • Figure 39. Cytori Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Cytori Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Bioheart Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Bioheart Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Universal Cells, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 44. Universal Cells, Inc. (Japan) Revenue: by Geography 2020
  • Figure 45. Athersys, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Athersys, Inc. (United States) Revenue: by Geography 2020
  • Figure 47. Geron Corp. (United States) Revenue, Net Income and Gross profit
  • Figure 48. Geron Corp. (United States) Revenue: by Geography 2020
  • Figure 49. Pluristem Therapeutics (Israel) Revenue, Net Income and Gross profit
  • Figure 50. Pluristem Therapeutics (Israel) Revenue: by Geography 2020
  • Figure 51. Fibrocell Science (United States) Revenue, Net Income and Gross profit
  • Figure 52. Fibrocell Science (United States) Revenue: by Geography 2020
  • Figure 53. Astellas US Holding, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 54. Astellas US Holding, Inc. (United States) Revenue: by Geography 2020
  • Figure 55. MEDIPOST Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 56. MEDIPOST Co., Ltd. (South Korea) Revenue: by Geography 2020
  • Figure 57. Anterogen Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 58. Anterogen Co., Ltd. (South Korea) Revenue: by Geography 2020
  • Figure 59. Pharmicell Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 60. Pharmicell Co., Ltd. (South Korea) Revenue: by Geography 2020
  • Figure 61. Holostem Terapie Avanzate S.r.l (Italy) Revenue, Net Income and Gross profit
  • Figure 62. Holostem Terapie Avanzate S.r.l (Italy) Revenue: by Geography 2020
  • Figure 63. JCR Pharmaceuticals Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 64. JCR Pharmaceuticals Co., Ltd. (Japan) Revenue: by Geography 2020
  • Figure 65. NuVasive, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 66. NuVasive, Inc. (United States) Revenue: by Geography 2020
  • Figure 67. RTI Surgical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 68. RTI Surgical, Inc. (United States) Revenue: by Geography 2020
  • Figure 69. AlloSource (United States) Revenue, Net Income and Gross profit
  • Figure 70. AlloSource (United States) Revenue: by Geography 2020
  • Figure 71. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 72. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 73. Gilead Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 74. Gilead Sciences (United States) Revenue: by Geography 2020
  • Figure 75. Global Stem Cell Therapy: by Type USD Million (2021-2026)
  • Figure 76. Global Stem Cell Therapy: by Application USD Million (2021-2026)
  • Figure 77. Global Stem Cell Therapy: by Cell Source USD Million (2021-2026)
  • Figure 78. Global Stem Cell Therapy: by End user USD Million (2021-2026)
  • Figure 79. South America Stem Cell Therapy Share (%), by Country
  • Figure 80. Asia Pacific Stem Cell Therapy Share (%), by Country
  • Figure 81. Europe Stem Cell Therapy Share (%), by Country
  • Figure 82. MEA Stem Cell Therapy Share (%), by Country
  • Figure 83. North America Stem Cell Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Cellular Dynamics International, Inc. (United States)
  • Osiris Therapeutics (United States)
  • Vcanbio Cell & Gene Corp. Ltd. (United States)
  • Gamida-Cell Ltd. (Israel)
  • Golden Meditech Holdings Limited (Hong Kong)
  • Celgene Corp. (United States)
  • Guanhao Biotech Co. (China)
  • Mesoblast Ltd. (Australia)
  • Vericel Corp. (United States)
  • Stemcell Technologies Inc. (Canada)
  • Beike Biotechnology co., Ltd. (China)
  • Cytori Therapeutics, Inc. (United States)
  • Bioheart Inc. (United States)
  • Universal Cells, Inc. (Japan)
  • Athersys, Inc. (United States)
  • Geron Corp. (United States)
  • Pluristem Therapeutics (Israel)
  • Fibrocell Science (United States)
  • Astellas US Holding, Inc. (United States)
  • MEDIPOST Co., Ltd. (South Korea)
  • Anterogen Co., Ltd. (South Korea)
  • Pharmicell Co., Ltd. (South Korea)
  • Holostem Terapie Avanzate S.r.l (Italy)
  • JCR Pharmaceuticals Co., Ltd. (Japan)
  • NuVasive, Inc. (United States)
  • RTI Surgical, Inc. (United States)
  • AlloSource (United States)
  • Novartis International AG (Switzerland)
  • Gilead Sciences (United States)
Additional players considered in the study are as follows:
Organogenesis Holdings (United States) , Vericel (United States) , Mesoblast Ltd.(Australia) , ReNueron Group plc,(United Kingdom) , International Stem Cell Corp. (United States)
Select User Access Type

Key Highlights of Report


May 2021 229 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Stem Cell Therapy Market Report?